BMS-181174

BMS-181174 is a synthetic aminodisulphide analogue of **mitomycin C** developed as an antitumor antibiotic with enhanced activity against a broad spectrum of cancer cell lines, including those resistant to mitomycin C[1][3][5]. Its mechanism of action is thought to involve **DNA interstrand cross-link formation**, leading to inhibition of DNA synthesis and consequent cell death, although the precise enzymatic activation pathway differs from mitomycin C[2][4]. BMS-181174 demonstrated anticancer activity in phase I/II clinical trials, showing responses in colorectal cancer, non-small-cell lung cancer, ovarian cancer, and gastrointestinal neoplasms; however, its development was discontinued due to toxicity, especially severe myelosuppression, pneumonitis, and thrombophlebitis[1][3][5]. The originator and main developer is **Bristol Myers Squibb**.

Other names

N-7-[2-(4-nitrophenyldithio)ethyl]mitomycin C